IGI Unveils First-in-Class ‘Triple-Threat’ Antibody Targeting Solid Tumors

NEW YORK, NY – May 20, 2026 – Ichnos Glenmark Innovation (IGI), a clinical-stage biotechnology company, today announced a significant step forward in its oncology pipeline with the unveiling of ISB 2301, a novel development candidate designed to combat solid tumors. Described as a first-in-class, multispecific immune cell activator, the antibody represents a highly engineered approach to cancer therapy, aiming to overcome the limitations that have challenged conventional immunotherapies.

The company is advancing ISB 2301 rapidly toward clinical trials, with plans to submit an Investigational New Drug (IND) application to regulators by the end of this year. If cleared, IGI expects to initiate human studies in 2027, bringing a new potential treatment option to patients battling a range of solid tumor cancers.

A Multi-Pronged Attack on Cancer's Complexity

At the heart of ISB 2301's design is a sophisticated strategy intended to outmaneuver the complex biology of solid tumors. Unlike many existing therapies that focus on a single target or a single type of immune cell, ISB 2301 deploys a multi-pronged attack. The molecule is engineered to simultaneously bind to three different tumor-associated antigens (TAAs), proteins often found on the surface of cancer cells.

This triple-targeting mechanism is a direct response to tumor heterogeneity, a major hurdle in cancer treatment where cells within a single tumor can vary significantly. By engaging multiple targets, the therapy aims to reduce the likelihood of cancer cells evading destruction, a common cause of treatment failure and relapse.

Beyond its multi-antigen approach, ISB 2301’s key innovation lies in its ability to rally two distinct arms of the immune system. The antibody is designed to activate both T cells and natural killer (NK) cells, creating a powerful and comprehensive anti-tumor response. T cells are the adaptive immune system's specialized soldiers, capable of recognizing and remembering specific cancer targets. NK cells, part of the innate immune system, provide a rapid, frontline defense and are particularly effective at destroying tumor cells that have learned to hide from T cells by downregulating their antigen-presenting machinery.

By engaging both cell types, ISB 2301 is hypothesized to create a synergistic effect, leveraging the unique strengths of each to achieve more potent and durable tumor destruction. IGI reports the antibody is also designed to induce potent antibody-dependent cellular cytotoxicity (ADCC), a mechanism where immune cells are directed to kill antibody-coated targets, as well as provide checkpoint inhibition to release the brakes on the immune system.

“We engineered ISB 2301 to match the biological complexity of solid tumors in a way that conventional immunotherapies have not been able to address,” said Lida Pacaud, M.D., President and Chief Executive Officer of IGI, in a statement. “By simultaneously targeting three tumor-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumors.”

Built on a Validated, Breakthrough Platform

The development of such a complex molecule was made possible by IGI’s proprietary BEAT® (Bispecific Engagement by Antibodies based on the TCR) technology. This platform is the company's core engine for innovation, enabling the design of full-length multispecific antibodies with favorable characteristics, including stability, extended half-lives, and, critically, robust manufacturability using standard industry processes.

The power and potential of the BEAT® platform received its most significant validation last year through a landmark collaboration for another of its assets, ISB 2001. That candidate, a first-in-class trispecific antibody for relapsed/refractory multiple myeloma, attracted a major licensing deal with pharmaceutical giant AbbVie. The agreement included a $700 million upfront payment and over a billion dollars in potential milestones, signaling strong industry confidence in the technology's ability to produce highly effective and valuable therapeutics.

That prior success not only provided IGI with substantial non-dilutive funding but also served as a clinical proof-of-concept for the platform itself. It demonstrated that the BEAT® technology could successfully generate complex antibodies capable of tackling difficult-to-treat cancers.

“The early-stage clinical success of our prior lead investigational asset, ISB 2001, was a defining moment for IGI in that it attracted a collaboration with AbbVie, validating not just the science, but the platform behind it,” Pacaud added. “It’s this same platform that provided the engineering capability to develop such a highly complex molecule as ISB 2301.”

Addressing a Critical Unmet Need in Solid Tumors

The announcement of ISB 2301 brings a new wave of hope to the challenging field of solid tumor oncology. While immunotherapies like checkpoint inhibitors have revolutionized care for some patients, a large proportion either do not respond or eventually develop resistance. Other advanced approaches like CAR-T cell therapy, highly successful in blood cancers, have struggled to demonstrate consistent efficacy in solid tumors due to challenges with tumor infiltration and an immunosuppressive tumor microenvironment.

ISB 2301 is engineered to confront these issues head-on. Its multi-faceted mechanism of action is tailored for the hostile environment of solid tumors, aiming to generate a more robust and sustained immune attack that can overcome resistance mechanisms. The favorable safety profile and excellent pharmacokinetics observed in preclinical non-human primate studies further bolster confidence as the candidate moves toward human trials.

With a clear development timeline and the scientific backing of its validated BEAT® platform, IGI is positioning itself as a key innovator in the next generation of cancer therapies. The advancement of ISB 2301 into the clinic will be a critical test of this novel approach, one that could potentially offer a much-needed new option for patients who have exhausted current standards of care. As the company prepares for its IND submission, the oncology community will be watching closely, hopeful that this multi-mechanistic strategy can unlock a new level of efficacy against some of the most formidable cancers.